Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 9/20 | 0.40 |
| ▸ | CNR1 | P21554 | 2/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.37 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.37 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23830396 | 0.85 | HSD17B10 (0.47) | HSD17B10ELANEHTR2C | |
| SCHEMBL23830291 | 0.80 | HSD17B10 (0.56) | HSD17B10 | |
| SCHEMBL23830372 | 0.78 | HSD17B10 (0.45) | HSD17B10GPR119HTR2C | |
| SCHEMBL15712129 | 0.78 | GPR119 (0.40) | HSD17B10GPR119 | |
| SCHEMBL16395514 | 0.75 | HSD17B10 (0.42) | HSD17B10ELANEHTR2C | |
| SCHEMBL22131921 | 0.75 | ACACB (0.49) | ACACBCNR2CNR1PARP15PARP10 | |
| SCHEMBL23830357 | 0.74 | PDE6D (0.40) | ACACBCNR2CNR1ELANE | |
| SCHEMBL2258738 | 0.73 | CA12 (0.42) | HSD17B10HTR2C | |
| SCHEMBL20022407 | 0.73 | POLB (0.41) | CNR2 | |
| SCHEMBL15968839 | 0.73 | PARP10 (0.41) | ACACBPARP15PARP10PARP2GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210292333-A1 | CONDENSED AZAHETEROARYL COMPOUNDS HAVING ANTIBACTERIAL ACTIVITY AGAINST TUBERCULOSIS BACTERIA | CADILA HEALTHCARE LIMITED (IN) | 2021-09-23 | — | — | US | disclosed |
| CN-112543757-A | Condensed azaheteroaryl compounds having antibacterial activity against tubercle bacillus | 卡迪拉保健有限公司 | 2021-03-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210292333-A1 | CONDENSED AZAHETEROARYL COMPOUNDS HAVING ANTIBACTERIAL ACTIVITY AGAINST TUBERCULOSIS BACTERIA | DPEP1, SAT1, PEPD | ACACB 1645/4885HSD17B10 1210/4885CNR2 4515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.